Table 1.
Baseline characteristics of patients who completed the study.
| Characteristics | Patients (n = 18) |
|---|---|
| Age, years | 51.3 ± 9.5 |
| Disease duration, years | 3.6 (1.6–5.3) |
| BMI, Kg/m2 | 37.2 ± 3.8 |
| BMI > 35 | 13 (72) |
| Comorbidities | |
| Hypertension | 11 (61) |
| Hyperlipidemia | 13 (72) |
| Non-alcoholic fatty liver disease | 8 (44) |
| Polycystic ovary syndrome | 2 (11) |
| Type 2 diabetes | 0 |
| Previous atherothrombotic events | 0 |
| Congestive heart failure | 0 |
| Neurodegenerative disorders | 0 |
| Medications | |
| Non-steroidal anti-inflammatory drugs | 8 (44) |
| Paracetamol | 7 (39) |
| Antidepressant | 5 (28) |
| Gabapentinoids | 3 (17) |
| Benzodiazepines | 3 (17) |
| Muscle relaxants | 1 (6) |
| Patient-reported outcomes | |
| FIQ | 61.7 ± 22.2 |
| HADS-A | 11.1 ± 4.0 |
| HADS-D | 9.6 ± 3.7 |
| EQ-5D utility score | 0.6 ± 0.2 |
| EQ-5D VAS | 42.0 ± 23.7 |
| SF-36 MCS | 34.3 ± 16.7 |
| SF-36 PCS | 30.3 ± 14.8 |
BMI, body mass index; EQ-5D, EuroQoL 5 dimensions; FIQ, fibromyalgia impact questionnaire; HADS-A, hospital anxiety and depression scale-anxiety; HADS-D, hospital anxiety and depression scale-depression; MCS, mental component score; PCS, physical component score; SF-36, 36-item short form health survey; VAS, visual analogue scale.